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ABSTRACT
Adenoviruses are emerging as a major cause of infectious complications after allogeneic transplantation. We
evaluated the incidence and outcome of symptomatic adenovirus infection or adenovirus disease after alemtu-
zumab-based reduced-intensity conditioning in 86 consecutive patients. The overall probability of adenovirus
disease was 18.4% (11/86 patients). Five patients died of progressive adenovirus disease, and this was the most
important infectious cause of mortality in this cohort. The probability of nonrelapse mortality was 49% in
patients with adenovirus disease compared with 25.5% in those without (P  .007). The severity of lympho-
cytopenia and continuation of immunosuppressive therapy were the most important risk factors for progressive
adenovirus disease and death. In contrast, patients who were not receiving immunosuppressive therapy or had
had it reduced or withdrawn cleared the virus. We also detected a correlation between the lack of preemptive
anti-cytomegalovirus (CMV) therapy for CMV reactivation and the risk of progressive adenovirus disease (P 
.05). Our findings highlight the emergence of adenovirus as an important posttransplantation pathogen even
after reduced-intensity conditioning and demonstrate the effect of the severity of lymphocytopenia, anti-CMV
prophylaxis, and immunosuppressive therapy on the outcome of adenovirus disease.
© 2004 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
Adenoviruses have been increasingly recognized as
n important pathogen after stem cell transplantation;
hey occur in 4.9% to 20.9% of allografted patients
1-8]. However, in the absence of prospective studies
ntil recently, it has been difﬁcult to evaluate both the
ctual incidence and the natural history of adenovirus
nfections and disease. In a recent prospective study
hat included both conventional and reduced-intensity
ransplantations, the incidences of adenovirus infec-
ion and disease were 45% and 27% in patients who
eceived alemtuzumab (Campath-1H; Schering, West
ussex, UK) in vivo [9]. In this context, it is notewor- c
86hy that in multicenter studies from the United King-
om of patients who received reduced intensity with
xactly the same conditioning regimen as in the afore-
entioned prospective study, there was a high inci-
ence of cytomegalovirus (CMV) [10] and respiratory
irus infections [11]. In contrast, however, there has
een no similar study of adenovirus infections that
ocuses exclusively on this group of patients who have
eceived alemtuzumab-based or any other reduced-
ntensity conditioning protocol [12-16], although
ome groups have reported on CMV and other infec-
ious complications [17,18].
We therefore now report the incidence and out-
ome of adenovirus disease in 86 patients, all of whom
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Adenovirus Infection after Reduced-Intensity Transplantation
Beceived alemtuzumab-based reduced-intensity condi-
ioning. This study includes patients from the study by
hakrabarti et al. [9] together with patients from
nother center, which conﬁrms and extends their pre-
ious ﬁndings.
ATIENTS AND METHODS
atients
Eighty-six patients underwent reduced-intensity
onditioning at 2 major collaborating centers between
une 1997 and October 2001. The eligibility criteria
or receiving reduced-intensity conditioning have
een previously described, and the study design was
pproved by the local ethics committees of the partic-
pating centers [10].
onditioning Regimen
Conditioning treatment consisted of alemtuzumab
Campath-1H, the immunoglobulin G1 humanized
onoclonal antibody against CD52; Therapeutic An-
ibody Center, Oxford, UK) 20 mg/d on days 8 to
4, ﬂudarabine 30 mg/m2 days 7 to 3, and mel-
halan 140 mg/m2 on day 2. Cyclosporine A was
tarted from day 1 as graft-versus-host disease
GVHD) prophylaxis. Patients received unmanipu-
ated peripheral blood stem cells from a matched fam-
ly donor or unmanipulated bone marrow from an
nrelated donor.
Donor lymphocyte infusion (DLI) was not a part
f the protocol and was at the discretion of the treat-
ng physician. The usual indications were persistent
ixed chimerism or the persistence, progression, or
elapse of the disease that warranted the transplanta-
ion.
MV Surveillance
Patients at risk of CMV infection were monitored
eekly from the start of conditioning treatment to 100
ays after transplantation by a qualitative polymerase
hain reaction (PCR) assay and were preemptively
reated with ganciclovir (GCV) 5 mg/kg twice daily as
he ﬁrst-line treatment or foscarnet 180 mg/kg in 3
ivided doses or at half of these doses for both drugs
f used in combination as second-line therapy. Two
atients at 1 center received cidofovir as ﬁrst-line
reatment as part of a clinical trial.
irology
Stool, urine, and throat samples were examined as
onsidered appropriate from patients who developed 1
r more of the following complications: fever not
esponding to antibacterial or antifungal therapy, di-
rrhea, upper respiratory illness, chest inﬁltrates, he-
atic enzyme abnormalities, urinary symptoms, and w
B&MTentral nervous system abnormalities. One of the cen-
ers, in addition, performed a surveillance study on
tool, urine, and throat samples before transplantation
nd weekly to fortnightly thereafter to 180 days after
ransplantation in 20 patients [9].
The specimens were cultured in rhesus monkey
idney cells and, according to individual center pro-
ocol, in human embryonic lung cells or Hep2 cells
nd primary liver carcinoma cell lines (Alexander
ells). The cell cultures were examined for cytopathic
ffects for 14 days. In addition, in the presence of
ppropriate symptoms, the stool and urine samples
ere also examined by electron microscopy. The tis-
ue samples of liver, lungs, or gut obtained before or
fter death were examined by electron microscopy,
ulture, or both. The virus isolates were conﬁrmed by
irect immunoﬂuorescence by using species-speciﬁc
uorescein-conjugated monoclonal antibodies (Dako
iagnostics, Cambridgeshire, UK). Specimens for
acteriologic and fungal investigations were concur-
ently processed by using standard methods of micros-
opy, culture, and sensitivity testing.
Peripheral blood samples were examined for pres-
nce of adenovirus DNA as previously described [9].
his was performed at 1 center as a part of a prospec-
ive study. At the other center, this was performed at
he discretion of the treating physician.
efinitions
The deﬁnitions used in this study were as de-
cribed previously [9]. We deﬁned adenovirus infec-
ion as the identiﬁcation of adenovirus from a surveil-
ance sample on culture or electron microscopy. The
resence of the virus together with appropriate symp-
oms in the absence of any other recognizable cause
as termed adenovirus disease. The isolation of ade-
ovirus from a tissue site with or without histologic
vidence of involvement was compatible with the def-
nition of deﬁnite disease. In the absence of tissue
iagnosis, the term probable adenovirus disease was
sed. In addition, if other pathogens that could explain
he symptoms were isolated from the same site, this
as termed probable adenovirus disease even in the
resence of a tissue diagnosis of adenovirus.
Gut biopsy with documentation of adenovirus in-
lusions was considered mandatory for deﬁning deﬁ-
ite disease. In those who did not undergo biopsy,
iarrhea was attributed to probable adenovirus disease
f no other organisms were identiﬁed and the symp-
oms improved with clearance of the virus or pro-
ressed with deﬁnite involvement of other sites.
Upper respiratory illness was deﬁned as the acute
nset of any rhinorrhea, sinusitis, pharyngitis, or
ough without clinical or radiologic evidence of lower
espiratory tract involvement or hypoxia combined
ith the detection of adenovirus in upper respiratory
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1ecretions, in the absence of other pathogens. Lower
espiratory illness was deﬁned as clinical signs and
ymptoms of lower respiratory involvement with ra-
iologic evidence of new pulmonary inﬁltrates with or
ithout hypoxia associated with detection of the virus
n sputum or bronchoalveolar lavage specimens. If
o-pathogens were detected and a bronchoalveolar
avage specimen was not available, lower respiratory
llness was deﬁned as probable. It is worth noting that
or upper respiratory infections, we did not depend on
istologic detection of adenoviruses in tissue biopsy
amples as evidence of adenovirus disease, because the
irus could establish persistent and latent infection in
he tonsils and adenoids. Respiratory samples were
creened for other respiratory viruses and cultures as
reviously described [11].
Any death that occurred in a patient with probable
r deﬁnite adenovirus disease was deﬁned as adenovi-
us-related death if there was histologic antemortem
r postmortem documentation or if death occurred
ithin 6 weeks of the onset of symptoms with persis-
ent isolation of adenovirus but without any other
dentiﬁable etiology. The absolute lymphocyte count
ALC) was deﬁned as the ALC at the onset of adeno-
irus infection.
All patients were monitored for gastrointestinal,
espiratory, and urinary symptoms. Documented in-
ections at other sites were also noted. GVHD was
raded according to standard criteria.
nterventions
Active therapy was performed according to the
able 1. Characteristics of Nonmyeloablative Transplant Recipients wit
Variable
edian age (y), range
ex (male/female)
isease
AML/ALL/MDS
CML/CLL
NHL/HD
Myeloma
revious transplantations
onor type
Related
Unrelated
ays to neutrophil count >0.5  109/L, median (range)
MV-seropositive recipient/donor
CV therapy
cute GVHD
None
Grade I/II
Grade III/IV*
hronic extensive GVHD
ML indicates acute myeloid leukemia; ALL, acute lymphocytic leu
CLL, chronic lymphocytic leukaemia; HD, Hodgkin disease; N
A total of 10 of 14 patients with grade III/IV GVHD developed ixisting policies of the units. Whereas 1 center offered w
88nly supportive care, the other center initiated antivi-
al therapy for severe adenovirus disease with intrave-
ous ribavirin or cidofovir, as previously described [9].
n addition, an active attempt was made to wean the
atients off the immunosuppression at the ﬁrst detec-
ion of an adenovirus isolate at 1 center, as reported
reviously. Intravenous immunoglobulin was not rou-
inely administered in the posttransplantation period.
tatistical Calculations
Univariate P values and odds ratios were calcu-
ated from 2  2 contingency tables by using Epi Info
ersion 6 (Centers for Disease Control and Preven-
ion, Atlanta, GA). Continuous variables were ana-
yzed by using the nonparametric Mann-Whitney test.
umulative probabilities were analyzed by the
aplan-Meier method, and the differences between
roups were compared by using log-rank 2 tests.
ESULTS
The patient characteristics are shown in Tables 1
nd 2. There was no difference in age, sex, or the
nderlying disease in terms of adenovirus disease. The
ime to neutrophil engraftment was also similar in the
groups.
ncidence and Pattern of Adenovirus Disease
Eleven patients developed adenovirus disease (3 of
hem were reported previously [9]; Table 2). The
verall probability of developing adenovirus disease
ithout Adenovirus Disease
h Adenovirus
(n  11)
Without Adenovirus
(n  75)
P
Value
7 (21-53) 43 (18-59) .3
7/4 52/23 .7
1/0/0 5/3/1
0/2 3/5 .9
5/1 31/12
2 15
3 33 .9
6 46 .7
5 29
.5 (10-23) 12.5 (8-45) .9
3 47 .04
2 39 .07
3 52
0/3 7/7 .01
3/2 7/2
2 3
MDS, myelodysplastic syndrome; CML, chronic myeloid leukemia;
on-Hodgkin disease; GCV, ganciclovir.
donor lymphocyte infusion.h and w
Wit
4
13
kemia;
HL, n
t afteras 18.4% (95% conﬁdence interval [CI], 8.4%-
Table 2. Characteristics and Outcome of Patients with Adenovirus Infections
Patient
No.
Age (y)/
Sex
Type of
Donor
Onset of
Adenovirus
Infection
(d) Sites Blood PCR Lymphocytes
GVHD
Grade
CyA/
Steroid
Adenovirus
Disease Antiviral
Other Virus
Infection
(non-CMV)
Outcome of
Adenovirus
Infection
1 47/M UD 127 Throat ND 1100 0 / UR (def) No IIA Improved
2* 50/F MSD 105 Stool Negative 290 0 W/ Gut (prob) No HSV Improved
3 46/M MSD 30 Stool, urine ND 100 0 R/ Gut (prob) No None Improved
4 47/M UD 291 Stool, sputum,
urine
Positive (day 295) 60 IV† C/C Gut/lung
(prob)
No None Died of
multiorgan
failure
(day 312)
5* 22/F MSD 19 Stool, urine,
liver
(autopsy)
Positive (day 31) 0 0 C/ Liver (def) Ribavirin None Died of
adenohepatitis
(day 44)
6 42/M MSD 42 Stool ND 130 0 W/W Gut (prob) No None Died of
encephalitis
7 38/M UD 113 Stool, throat,
sputum,
liver
Positive (day 117) 300 III C/C Gut (prob)/
liver (def)
No None Died of
adenohepatitis
(day 130)
8* 52/M UD 90 Stool, throat Negative 210 0 W/ UR (def) No HZV Improved
9 49/F MSD 48 Stool ND 170 III C/W Gut (prob) No None Improved
10 53/M MSD 560 Stool ND 150 IV† C/C Gut/lung,
liver
(prob)
No None Died of
multiorgan
failure
(day 593)
11 44/F UD 17 Liver
(autopsy)
ND 100 IV C/C Liver (def) No Died of
adenohepatitis
(day 58)
M indicates male; F female; MSD, matched sibling donor; UD, unrelated donor, UR, upper respiratory; CyA, cyclosporin A; C, continued; R, reduced; W, withdrawn; def, deﬁnite; prob, probable; ND,
not done; HSV, herpes simplex virus; HZV, herpes zoster virus; Inﬂ, inﬂuenza.
*Patients reported in a previous prospective study [9].
†After DLI.
A
denovirus
Infection
after
R
educed-Intensity
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ransplantation
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18.4%). Six were categorized as probable and 5 as
eﬁnite adenovirus disease (Table 1). Three patients
ad multiorgan involvement. Probable gut involve-
ent was documented in 7 patients. Three patients
ad biopsy-proven evidence of adenovirus hepatitis,
nd another had probable hepatitis. Probable lower
espiratory disease and deﬁnite upper respiratory dis-
ase were diagnosed in 2 patients each.
The median time to adenovirus disease was 90
ays (Figure 1). All but 2 patients had the onset of
isease within the ﬁrst 4 months. Two patients with
ate-onset adenovirus disease (days 291 and 560) had
vidence of adenovirus disease after the development
f GVHD after DLI.
denovirus-Related Mortality
Five of 11 patients with adenovirus disease died
ithin 6 weeks of the onset of clinical symptoms,
ithout any deﬁnite evidence of an unrelated etiology.
he overall probability of adenovirus-related death
as 8.8% (95% CI, 2%-16%). The death was deﬁ-
itely attributable to adenovirus in 3 of them (patients
, 7, and 11) by histologic evidence; all died of liver
ailure. Blood PCR was checked in 2 of them (patients
and 7), and both were positive approximately 2 to 3
eeks before their deaths. In the other 2 patients, the
ircumstantial evidence of improvement in GVHD-
elated symptoms before progression of adenovirus
isease and death, in the absence of other pathogens,
uggested adenovirus disease to be the principal con-
ributor to the fatal outcomes. One patient (patient 4)
ith grade III to IV GVHD that improved on steroids
nd cyclosporine died of multiorgan failure after pro-
ressive respiratory involvement and diarrhea within 3
igure 1. Incidence of adenovirus disease after reduced-intensity
ransplantation.eeks of isolation of adenovirus from stool, urine, and e
90putum samples. Blood PCR was ﬁrst positive 2 weeks
efore death. This patient had no other pathogen
solated from any site. Another patient (patient 10)
ad adenovirus isolation from stool after he developed
evere GVHD after DLI. This patient was treated
ith steroids and antilymphocyte globulin and expe-
ienced improvement of GVHD. He presented with
iarrhea and succumbed to multiorgan failure 17 days
ater, and there was evidence of severe hepatitis before
emise. Adenovirus was the only pathogen repeatedly
solated from the stool samples until demise. The
linical course in this patient mimicked that of other
atients dying from disseminated adenovirus disease.
nfortunately, a blood PCR sample was not obtained,
nd permission for autopsy studies could not be ob-
ained in this patient.
All the patients who died of deﬁnite or probable
denovirus disease were receiving continued immuno-
uppressive therapy. Two of them (patients 4 and 11)
ere taking steroids and cyclosporin A for GVHD,
hich was continued. Two other (patients 7 and 10)
eceived antithymocyte globulin in addition. The
hird patient (patient 5) was taking continued cyclo-
porin A because of poor graft function.
In contrast, none of patients who developed ade-
ovirus disease and had the immunosuppressive ther-
py withdrawn or reduced or were not receiving im-
unosuppressive therapy died of adenovirus disease
patients 1, 2, 3, 8, and 9). Two of those with diarrhea
ad adenovirus isolated from stool samples without
ny co-pathogen. Another patient had biopsy-proven
olitis but had Clostridium difﬁcile toxin detected in
tool samples (thus termed probable adenovirus dis-
ase) [9]. Clearance of adenovirus was associated with
mprovement in gut symptoms in all 3 patients. The
ther 2 patients had severe upper respiratory illness
hat improved after clearance of adenovirus from na-
opharyngeal aspirates and throat samples. There was
o evidence of other respiratory viruses on direct
mmunoﬂuorescence and culture. Three patients (pa-
ients 2, 8, and 9) receiving steroids, cyclosporin A, or
oth had the immunosuppression reduced or with-
rawn after isolation of the adenovirus and recovered
rom probable adenovirus disease. Patients 1 and 3
ere not receiving any immunosuppression at the
nset of adenovirus disease and had a very brief dura-
ion of symptoms.
Another patient (patient 6) who died presented
ith diarrhea and progressive extrapyramidal symp-
oms. Adenovirus was isolated from stool samples. He
as on a tapering schedule of cyclosporin A and
leared the virus within 2 weeks, with improvement in
iarrhea. This patient was found to have progressive
esions in the basal ganglia on repeated scans before
is demise, and this was suspected to be of fungal
tiology.
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Adenovirus Infection after Reduced-Intensity Transplantation
Blood PCR and Isolation of Virus from Multiple
ites
PCR assay on blood was performed in 5 patients.
hree patients had a positive PCR assay and suc-
umbed to adenovirus disease within 2 to 3 weeks.
wo patients with a negative PCR improved and
leared the virus.
Isolation of adenovirus from multiple sites (1
ite) did not correlate with increased mortality in this
ohort (3/5 patients with compared with 2/6 patients
ithout adenovirus-related mortality; P  .56). How-
ver, adenovirus was isolated from more than 2 sites
nly in patients with a fatal outcome (3/5 compared
ith none of the 6 patients who improved; P  .18).
MV Serostatus and Anti-CMV Therapy
Adenovirus disease was more common in CMV
ow-risk patients (P .04; Table 1). There was a trend
oward a negative correlation between anti-CMV
herapy and the risk of adenovirus disease (2/41 re-
eiving GCV compared with 9/45 not receiving anti-
MV therapy; P  .07). Out of 41 patients, 39 re-
eived GCV and the other 2 received cidofovir.
owever, none of the 41 patients who received anti-
MV therapy developed progressive adenovirus dis-
ase, compared with 5/45 patients who did not receive
reventative anti-CMV therapy (P  .05).
VHD and Immunosuppressive Therapy
GVHD occurred more frequently in patients with
denovirus disease (8/11 versus 23/75; P  .06; log-
ank test). However, active GVHD that necessitated
igure 2. A scatter plot showing the relationship between adeno-
irus-related deaths and absolute lymphocyte count (y-axis) in rela-
ion to the immunosuppressive therapy (IST; x-axis). The circles
nd crosses represent patients with and without adenovirus-related
eaths, respectively.mmunosuppressive therapy at the time of adenovirus t
B&MTisease was documented in only 5 patients (5/11 versus
3/75; P  .4; log-rank test). More patients with
rogressive adenovirus disease had GVHD, but this
as not statistically signiﬁcant (4/5 versus 1/6; P  .2;
og-rank test). However, irrespective of concurrent
VHD, patients who received continued immuno-
uppressive therapy were more likely to develop pro-
ressive adenovirus disease and die from it (5/5 versus
/6 patients not on continued immunosuppressive
herapy; P  .01; log-rank test).
bsolute Lymphocyte Count
The ALC at the onset of adenovirus disease was
mean  SD) 237  200/mm3 (Figure 2). The ALC
or the patients who died was signiﬁcantly lower than
n those who survived (122  113/mm3 versus 447 
93/mm3; P  .01). No threshold value for ALC was
igniﬁcantly associated with adenovirus-related mor-
ality. However, there was a trend toward more ade-
ovirus-related mortality in patients with ALC 200/
m3 (4/6 adenovirus-related deaths in patients with
LC 200/mm3 compared with 1/5 in those with a
igher ALC; P  .1; log-rank test).
isk Factors for Progressive Adenovirus Disease
nd Death
The occurrence of adenovirus disease or death was
ot correlated with recipient age, donor type, sex, or
nderlying disease (Table 1). There was a trend to-
ard more adenovirus-related mortality among pa-
ients who were not receiving anti-CMV therapy.
On univariate analysis, only continued immuno-
uppressive therapy and severe lymphocytopenia were
igniﬁcantly associated with increased mortality in pa-
ients with adenovirus disease (Figure 2). A multivar-
ate analysis was not performed because of the small
umber of patients in the cohort who developed ad-
novirus disease.
onrelapse Mortality
Twenty-two patients died from nonrelapse causes.
denovirus accounted for the most nonrelapse mor-
ality (n  5), followed by CMV (deﬁnite, n  2;
robable, n  2), respiratory viruses (n  2), Epstein-
arr virus (EBV; n  2), and fungus (n  2) as
nfectious causes. The probability of nonrelapse mor-
ality in patients with adenovirus disease was 49.1%
95% CI, 17%-81.2%), compared with 25.5% (95%
I, 14.5%-36.5%) in patients without adenovirus dis-
ase (P  .007; Figure 3).
ISCUSSION
With an improved understanding of the biology
nd immunology of CMV and EBV after stem cell
ransplantation, the preventative aspects of these in-
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1ections have vastly improved, resulting in a reduction
n mortality related to these viruses [19,20]. However,
eaths related to other viruses, such as adenoviruses
1-9], have been on the increase because effective
revention or therapeutic strategies for these patho-
ens have not yet been developed. Several retrospec-
ive studies on adenoviruses have suggested a role of
mmunosuppression in the pathogenesis of adenovirus
isease [2,3,5], but it was not until recently that the
elationship between the extent of T-cell depletion,
mmune recovery, immunosuppressive treatment, and
he progression of adenovirus infection was conclu-
ively demonstrated in a prospective study [9]. In the
ame study, adenovirus infections were shown to be
ncreased after the use of alemtuzumab in vivo in both
yeloablative and reduced-intensity transplantations.
We further attempted to investigate the outcome
f symptomatic adenovirus infections after alemtu-
umab-based reduced-intensity conditioning regi-
ens in a larger cohort that included patients from the
reviously mentioned prospective study [9]. The me-
ian time for the onset of adenovirus disease was 90
ays, which was similar to the pattern previously de-
cribed in adult transplant recipients [2,9]. Only 2
atients had adenovirus disease beyond 4 months after
ransplantation that were related to intensive immu-
osuppressive therapy for severe GVHD after DLI.
There is a lack of uniformity in deﬁning adenovi-
us disease in the published studies. We have followed
he deﬁnitions used in a previous publication by in-
estigators from our group [9]. However, the criteria
or deﬁning probable and deﬁnite adenovirus diseases
eed to be revisited since the documentation of the
igniﬁcance of detection of adenovirus DNA in blood
y PCR-based assays. It is often difﬁcult to be abso-
utely certain of the exact contribution of adenovirus
igure 3. Nonrelapse mortality among reduced-intensity transplant
ecipients in relation to adenovirus disease.o mortality, even after postmortem examination, par- p
92icularly in the presence of GVHD or other infec-
ions. In the absence of histologic evidence, we have
onsidered deaths to be probably related to adenovirus
nly if they occurred within 6 weeks of the onset of
denovirus disease in the absence of other deﬁnite
tiologic agents and persistent isolation of other vi-
uses. For the sake of uniformity in future trials, the
eﬁnitions of adenovirus disease and death need to be
greed on in a consensus meeting.
This study extends previous observations of the
ole of lymphocyte recovery and immunosuppressive
herapy on the outcome of adenovirus infections [9].
he most important observation was that the patients
eceiving continued immunosuppression were at the
ighest risk of a fatal outcome. Reduction of immu-
osuppression resulted in clinical improvement and
learance of the virus. Steroid use was the strongest
isk factor for CMV disease and death [19], and the
ame seems to be true for the outcome of adenovirus
isease as well. This strongly suggests that similar to
MV and EBV, the containment of adenovirus in the
osttransplantation setting is dependent on the recon-
titution of adenovirus-speciﬁc immunity, the kinetics
f which are determined by the speed of immune
econstitution and the use of immunosuppressive
herapy. Although almost all the patients with adeno-
irus disease had an ALC 300/mm3, it may not be
rudent to assume that there is such a critical value of
LC. Instead, this simply reﬂects the severity of lym-
hocytopenia, and this might vary in different clinical
ituations. In a recent report on pediatric transplant
ecipients [20], a similar outcome of adenovirus infec-
ions in relation to the severity of lymphocytopenia
as documented; an ALC 200/mm3 correlated with
ortality. We also found that the risk of adenovirus-
elated mortality tended to be higher in patients with
LC 200/mm3. However, more important than the
LC at a single time point is the failure of the lym-
hocyte counts to improve during the course of ade-
ovirus infection.
It might be hypothesized on the basis of the ﬁnd-
ngs from this study and others [9,20] that, in patients
ith previous exposure to adenovirus, after allogeneic
ransplantation adenovirus might reactivate from lym-
hoepithelial tissues of the gut or upper respiratory
ract, with no or localized symptoms. The further
utcome of adenovirus infection would depend on the
bility of the host immune system to contain the viral
eplication. If the patient is not severely lymphocyto-
enic and is not receiving continued immunosuppres-
ion, adenovirus infection is likely to remain localized
nd improve, such as in patients 1, 2, 3, 6, 8, and 9.
hose who are severely lymphocytopenic and are re-
eiving continued immunosuppression are likely to
ave disseminated disease, which is usually preceded
y a period of asymptomatic viremia. Persistent lym-
hopenia is most commonly due to continued inten-
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Adenovirus Infection after Reduced-Intensity Transplantation
Bive immunosuppressive therapy, which hampers the
ymphocyte recovery. The withdrawal or reduction of
he immunosuppressive therapy might not be easily
chievable in the presence of GVHD but should be
onsciously attempted if adenovirus is isolated. The
se of high-dose antithymocyte globulin results in
evere lymphopenia that is not immediately reversible
nd could contribute to a high incidence of mortality
rom adenovirus even in the late posttransplantation
eriod. Patients receiving high doses of steroids or
ther immunosuppressive therapies are candidates for
ntensive surveillance for adenovirus and should re-
eive preemptive therapy as discussed below. Ulti-
ately we need to investigate the kinetics of adenovi-
us-speciﬁc T-cell reconstitution in relation to the
rogression of adenovirus infection and develop adop-
ive immunotherapy for patients at risk of adenovirus
isease.
Antiviral therapy in the treatment of progressive
ntiviral disease has been dismal [21,22]. In this con-
ext, our observation of the inverse correlation be-
ween prolonged preemptive GCV use for CMV re-
ctivation and progressive adenovirus disease is of
nterest. Although this might be only a chance obser-
ation given the small number of patients, prolonged
nti-CMV therapy might have a suppressive effect on
denovirus replication, and this has been suggested by
recent retrospective study as well [23]. A protective
ffect of GCV prophylaxis on severe resistant herpes
implex virus infections has also been reported [24].
owever, the effect of GCV on adenoviruses in vitro
s only moderate, and these ﬁndings resemble the
eduction of CMV deaths with the use of high-dose
cyclovir despite its having a weak anti-CMV effect
25]. These ﬁndings, in addition, further highlight the
act that patients not at risk of CMV disease might still
e at risk of severe complications related to adenovi-
uses or other viruses if the graft is T-cell depleted or
f GVHD supervenes.
Similar to CMV, a preemptive strategy to initiate
ntiviral therapy at the onset of adenovirus infection,
hen the patient is still asymptomatic, needs to be
eveloped. Viremia, as diagnosed by the presence of
denovirus DNA in peripheral blood, has been the
ost important predictor of disseminated disease and
dverse outcome [9,20,26]. This has been documented
o a limited extent in our study as well. Although a
CR assay on whole-blood samples might guide such
reatment, as suggested by 2 prospective studies
9,26], continued immunosuppressive therapy and
oor lymphocyte recovery could be additional indica-
ions for initiation of treatment [9]. Our data suggest
hat although most adenovirus infections are likely to
ccur in the ﬁrst 150 days after transplantation, pa-
ients who receive intensive immunosuppression at
ny stage, even 18 months, after transplantation are h
B&MTt an increased risk of severe adenovirus infection, as
videnced in patients 4 and 10. Surveillance and pre-
mptive strategies should thus be tailored according to
he clinical situation beyond 150 days after transplan-
ation. The choice of antiviral agents is limited to
ibavirin and cidofovir. The efﬁcacy of either of these
gents has not been conclusively proven, although
oth drugs are effective in vitro [22]. Whether such an
pproach would be effective and, if so, which antiviral
gent should be preferred can be answered only
hrough multicenter randomized trials.
In this cohort of patients, the incidence of adeno-
irus disease was higher than that of CMV disease and
ccounted for the highest mortality amongst the non-
elapse causes. This highlights the emerging role of
his virus and the urgency to improve the understand-
ng of its biology and prevent this fatal complication.
e previously reported a high incidence of both
MV and respiratory viruses after reduced-intensity
onditioning with alemtuzumab [10,11]. In keeping
ith these ﬁndings, adenovirus disease was docu-
ented in nearly one ﬁfth of the patients. Alemtu-
umab, when used at a high dose in vivo, has already
een shown to impair immune reconstitution, and this
as the main predisposing factor for adenovirus dis-
ase. However, when GVHD supervenes in an already
ragile immune system and the patients are exposed to
eavy immunosuppressive therapy, adenovirus infec-
ions can rapidly progress to disseminated disease and
eath. In view of these ﬁndings, the role of adenovi-
uses in other reduced-intensity conditioning proto-
ols that are associated with a high incidence of severe
VHD requiring immunosuppressive therapy needs
o be studied prospectively.
In conclusion, adenovirus accounted for most of
he infection-related deaths after alemtuzumab-based
educed-intensity transplantation. Lack of anti-CMV
rophylaxis, severe lymphocytopenia, and continued
mmunosuppressive therapy were associated with a
rogression of adenovirus infection and fatal outcome.
outine surveillance and preemptive therapy may pre-
ent mortality associated with adenovirus. Finally, a
etter understanding of adenovirus-speciﬁc immunity
n the posttransplantation setting would enable the
evelopment of novel immunotherapeutic strategies.
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